Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

941
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
941
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

819
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
819
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

367
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adult-Onset Still's Disease.

The New England journal of medicine·2026
Same author

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.

BMJ open·2026
Same author

Case report: a rare case of left-sided sinus of Valsalva aneurysm with concomitant coronary artery fistula and carotid artery aneurysm.

European heart journal. Case reports·2025
Same author

Understanding the Role of Epithelial Cells in the Pathogenesis of Systemic Sclerosis.

Cells·2025
Same author

Chilblain lupus induced by infliximab therapy.

Rheumatology advances in practice·2025
Same author

Global weakness with no clear precipitant: thymoma presenting as a necrotising myositis and myasthenia gravis overlap syndrome.

BMJ case reports·2025

Related Experiment Video

Updated: Jun 29, 2025

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.2K

Isotretinoin-induced myositis.

Oliver Hague1, Vasiliki Thanopoulou1, Pamela Mangat1

  • 1Department of Rheumatology, Royal Free Hospital, London NW3 2QG, United Kingdom.

Oxford Medical Case Reports
|March 27, 2024
PubMed
Summary

Isotretinoin can cause myositis (muscle inflammation), even after long-term use. This condition may appear asymmetrical and initially worsen after stopping the drug before responding to corticosteroid treatment.

More Related Videos

Induction of Acute Skeletal Muscle Regeneration by Cardiotoxin Injection
07:39

Induction of Acute Skeletal Muscle Regeneration by Cardiotoxin Injection

Published on: January 1, 2017

22.1K
In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells
08:35

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells

Published on: June 12, 2017

10.2K

Related Experiment Videos

Last Updated: Jun 29, 2025

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.2K
Induction of Acute Skeletal Muscle Regeneration by Cardiotoxin Injection
07:39

Induction of Acute Skeletal Muscle Regeneration by Cardiotoxin Injection

Published on: January 1, 2017

22.1K
In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells
08:35

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells

Published on: June 12, 2017

10.2K

Area of Science:

  • Dermatology
  • Neurology
  • Rheumatology

Background:

  • Retinoid medications, particularly isotretinoin, are widely used for acne treatment.
  • Retinoid-induced myositis is a rare but documented adverse effect.
  • Understanding its clinical presentation and management is crucial for patient safety.

Observation:

  • An 18-year-old male patient developed myositis during extended isotretinoin therapy.
  • The myositis presented with asymmetrical muscle involvement.
  • Clinical and biochemical markers of myositis initially progressed after isotretinoin cessation.

Findings:

  • Myositis can manifest after prolonged isotretinoin exposure.
  • Asymmetrical presentation does not exclude isotretinoin-induced myositis.
  • Delayed improvement and initial worsening post-discontinuation are characteristic.

Implications:

  • Clinicians should consider isotretinoin-induced myositis in the differential diagnosis of muscle inflammation, even with atypical features.
  • Awareness of potential delayed progression is important for patient monitoring.
  • Corticosteroid therapy is an effective treatment for this condition.